摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-cyclopropyl-3-(7-hydroxy-1-oxo-1H-isoquinolin-2-yl)-4-methylbenzamide | 895568-26-0

中文名称
——
中文别名
——
英文名称
N-cyclopropyl-3-(7-hydroxy-1-oxo-1H-isoquinolin-2-yl)-4-methylbenzamide
英文别名
N-cyclopropyl-3-(7-hydroxy-1-oxoisoquinolin-2(1H)-yl)-4-methylbenzamide;N-cyclopropyl-3-(7-hydroxy-1-oxoisoquinolin-2-yl)-4-methylbenzamide
N-cyclopropyl-3-(7-hydroxy-1-oxo-1H-isoquinolin-2-yl)-4-methylbenzamide化学式
CAS
895568-26-0
化学式
C20H18N2O3
mdl
——
分子量
334.375
InChiKey
GXRPQRCVHAILHR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    599.4±50.0 °C(Predicted)
  • 密度:
    1.38±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    25
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    69.6
  • 氢给体数:
    2
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Novel compounds 329
    申请人:Martin Barrie
    公开号:US20080207596A1
    公开(公告)日:2008-08-28
    The invention concerns a compound of formula (I) or pharmaceutically-acceptable salts thereof wherein R 1 , R 2 , R 3 , R 4 , R 5 and m are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.
    本发明涉及式(I)的化合物或其药学上可接受的盐,其中R1、R2、R3、R4、R5和m如规范中所定义,其制备过程,包含它们的制药组合物以及它们在治疗由细胞因子介导的疾病或医疗条件中的用途。
  • Amide Derivatives
    申请人:Nash Ian Alun
    公开号:US20080146566A1
    公开(公告)日:2008-06-19
    The invention concerns a compound of the Formula I (A chemical formula should be inserted here—please see paper copy enclosed herewith) wherein m is 0-2 and each R1 is a group such as hydroxy, halogeno, trifluoromethyl heterocyclyl and heterocyclyloxy; R2 is halogeno, trifluoromethyl or (1-6C)alkyl; R3 is hydrogen, halogeno or (1-6C)alkyl; and R4 is (3-6C)cycloalkyl; or pharmaceutically-acceptable salts thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.
    本发明涉及一种化合物,其化学式为I(化学式应在此处插入,请参见随附的纸质副本),其中m为0-2,每个R1是如羟基,卤素,三氟甲基杂环基和杂环氧基等基团; R2是卤素,三氟甲基或(1-6C)烷基; R3是氢,卤素或(1-6C)烷基; R4是(3-6C)环烷基; 或其药学上可接受的盐; 制备它们的方法,含有它们的制药组合物以及它们在治疗由细胞因子介导的疾病或医疗情况中的用途。
  • ISOQUINOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASES
    申请人:Martin Barrie
    公开号:US20100234355A1
    公开(公告)日:2010-09-16
    The invention concerns a compound of formula (I) or pharmaceutically-acceptable salts thereof wherein R 1 , R 2 , R 3 , R 4 , R 5 and m are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.
    本发明涉及化合物(I)或其药学上可接受的盐,其中R1、R2、R3、R4、R5和m在规范中定义,以及其制备过程、包含它们的制药组合物以及它们在治疗由细胞因子介导的疾病或医疗条件中的应用。
  • Amide derivatives
    申请人:AstraZeneca AB
    公开号:US07786115B2
    公开(公告)日:2010-08-31
    The invention concerns a compound of the Formula I wherein m is 0-2 and each R1 is a group such as hydroxy, halogeno, trifluoromethyl heterocyclyl and heterocyclyloxy; R2 is halogeno, trifluoromethyl or (1-6C)alkyl; R3 is hydrogen, halogeno or (1-6C)alkyl; and R4 is (3-6C)cycloalkyl;or pharmaceutically-acceptable salts thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.
    本发明涉及一种化合物,其化学式为I,其中m为0-2,每个R1是羟基、卤素、三氟甲基杂环基和杂环氧基等基团;R2为卤素、三氟甲基或(1-6C)烷基;R3为氢、卤素或(1-6C)烷基;R4为(3-6C)环烷基;或其药学上可接受的盐;制备它们的过程、含有它们的制药组合物以及它们在治疗细胞因子介导的疾病或医疗条件中的使用。
  • WO2006/67444
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多